ersonal use only
'Meet the CEO, Life Sciences Edition'
James Bonnar, Nyrada CEO
3 March 2022│Sydney NSW
Authorised by Mr. John Moore, Non-Executive Chairman, on behalf of the Board.
Important Notice & Disclaimer
This presentation has been prepared by Nyrada Inc (NYR or the Company). It should | Although the Company believes that the expectations reflected in the forward-looking | ||||||
only | statements are reasonable, none of the Company, its Directors or officers can give, or | ||||||
not be considered as an offer or invitation to subscribe for, or purchase any shares in | |||||||
NYR, or as an inducement to purchase any shares in NYR. No agreement to subscribe | gives, any assurance that the results, performance or achievements expressed or | ||||||
for securities in NYR will be entered into on the basis of this presentation or | any | implied by the forward-looking statements contained in this document will actually occur | |||||
i formation, opinions or conclusions expressed in the course of this presentation. | or that the assumptions on which those statements are based are exhaustive or will | ||||||
This presentation is not a prospectus, product disclosure document, or other offering | prove to be correct beyond the date of its making. | ||||||
d cument under Australian law or under the law of any other jurisdiction. It has been | Readers are cautioned not to place undue reliance on these forward-looking | ||||||
prepared for information purposes only. This presentation contains general summary | statements. Except to the extent required by law, the Company has no intention to | ||||||
use | update or revise forward-looking statements, or to publish prospective financial | ||||||
information and does not take into account the investment objectives, financial situation | |||||||
and particular needs of an individual investor. It is not a financial product advice, and | information in the future, regardless of whether new information, future events or any | ||||||
the Company is not licensed to, and does not provide, financial advice. | other factors affect the information contained in this presentation. | ||||||
This presentation may contain forward-looking statements which are identified by words | Readers should make their own independent assessment of the information and take | ||||||
s ch as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other | their own independent professional advice in relation to the information and any | ||||||
similar words that involve risks and uncertainties. These statements are based on an | proposed action to be taken on the basis of the information. To the maximum extent | ||||||
assessment of past and present economic and operating conditions, and on a number | permitted by law, the Company and its professional advisors and their related bodies | ||||||
ersonal | corporate, affiliates and each of their respective directors, officers, management, | ||||||
of assumptions regarding future events and actions that, as at the date of this | |||||||
presentation, are expected to take place. Such forward-looking statements do not | employees, advisers and agents and any other person involved in the preparation of | ||||||
guarantee of future performance and involve known and unknown risks, uncertainties, | this presentation disclaim all liability and responsibility (including without limitation and | ||||||
assumptions and other important factors many of which are beyond the control of the | liability arising from fault or negligence) for any direct or indirect loss or damage which | ||||||
Company, its Directors and management. | may arise or be suffered through use of or reliance on anything contained in, or omitted | ||||||
from, this presentation. Neither the Company nor its advisors have any responsibility or | |||||||
obligation to update this presentation or inform the reader of any matter arising or | |||||||
coming to their notice after the date of this presentation document which may affect any | |||||||
matter referred to in the presentation. | |||||||
NYRADA INC (ASX:NYR) | 2 | INVESTOR PRESENTATION | |||||
Company Overview
only | • Two lead drug development programs with significant | |||||||
therapeutic and commercial potential: | ||||||||
• Cholesterol-Lowering Program | ||||||||
• Brain Injury Program | ||||||||
use | • Collaborations with world leading institutions, Walter Reed | |||||||
Army Institute of Research (WRAIR) and UNSW Sydney | ||||||||
• Funding secured to complete Phase I studies | ||||||||
• Commercially focused business model | ||||||||
ersonal | • Experienced Board of Directors with impressive track record in | |||||||
biotech | ||||||||
NYRADA INC (ASX:NYR) | 3 | INVESTOR PRESENTATION | ||||||
Nyrada Board of Directors
onlyuse ersonalNYRADA INC (ASX:NYR)
Mr John Moore | Dr IanDixon | Christopher Cox | Mr Peter Marks | Mr Marcus Frampton | Dr Rüdiger Weseloh |
Non-Executive | Non-Executive | Non-Executive | Non-Executive | Non-Executive | Non-Executive |
Chairman | Director | Director | Director | Director | Director |
- Nyrada operates under the direction of a board of international calibre
- Track record in finding and realising the value of biotech companies
4 | INVESTOR PRESENTATION | |
Vision & Strategy
• To improve lives and offer hope through innovation
• Deliver novel treatments for diseases where:
only | • There is unmet clinical need; or |
• Current treatments are suboptimal | |
use | |
Our strategy is to advance highly optimised drug candidates towards a key value inflection point, such as an efficacy signal, and out-licencethem early, where the risk reward equation is most favourable for Nyrada shareholders
NYRADA INC (ASX:NYR) | 5 | INVESTOR PRESENTATION | ||
ersonal |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Nyrada Inc. published this content on 01 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 March 2022 22:20:38 UTC.